Nairobi: Across Africa, cancer medications have been found to be substandard or counterfeit, posing a serious health risk to patients. The alarming discovery suggests that nearly 20% of cancer drugs in four African countries may not contain the necessary ingredients to treat the disease effectively, potentially causing harm to those who rely on them.
According to Deutsche Welle, this issue highlights a complex challenge in regulating therapeutics across the continent. While previous studies have reported similar concerns with antibiotics, antimalarial, and tuberculosis drugs, this is the first significant study to identify high levels of defective or falsified anticancer drugs in circulation. Lutz Heide, a pharmacist at the University of Tübingen in Germany, affirmed the importance of such a systematic study, emphasizing that it sheds light on an unmeasured problem.
The causes of these defective products are varied, as explained by Marya Lieberman, the investigation's senior researcher from the University of Notre Dame. Issues can arise from manufacturing faults, poor storage conditions, or counterfeit drugs that misrepresent their contents. Visual inspections are often inadequate, as only a quarter of substandard products were identified this way; laboratory testing discovered the remainder.
Lieberman suggests that addressing this issue requires improved regulation, screening technologies, and training. Existing facilities in sub-Saharan countries often lack the capabilities for safe handling and analysis of toxic cancer medications.
The issue extends beyond cancer treatments. Nearly a decade ago, the World Health Organization found that around one in ten medicines in low and middle-income countries were substandard or falsified. The economic implications are significant, as countries might waste resources on ineffective medications, according to health economist Sachiko Ozawa.
High-income countries benefit from stringent regulatory systems and secure supply chains, but such infrastructure is lacking in many regions. This deficiency drives patients to less-regulated marketplaces, exacerbating the problem.
In response, the WHO is collaborating with the affected countries to tackle the issue, emphasizing the need for improved regulatory frameworks to prevent such incidents. The WHO's previous recommendations focus on prevention, detection, and response to mitigate the impact of substandard and falsified medicines.
Despite the challenges, there is hope. A majority of the cancer drugs tested in the study met required standards, indicating that quality suppliers do exist. However, the presence of some suppliers with a high number of failing samples remains a concern.